Long-term Outcome of End-stage Renal Disease Patients Treated With Hig-efficiency Hemodiafiltration

Study Overview
=================
Brief Summary
-----------------
A retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in King Chulalongkorn Memorial Hospital between 2001-2013 to determine the survival rate as well as other long-term outcome.

Detailed Description
-----------------
Growing evidences suggested the superiority of high-efficiency hemodiafiltration (HDF) which could provide both diffusion and convection in a single therapy compared with the conventional hemodialysis. However, the long-term, upto 10 years, outcome still limited. This retrospective cohort study was conducted in 66 end-stage renal disease patients who underwent high-efficiency hemodiafiltration technique in a single-center, King Chulalongkorn Memorial Hospital, between 2001-2013 to determine the survival rate as well as other long-term outcome

Official Title
-----------------
Long-term Outcome of End-stage Renal Disease Patients Treated With High-efficiency Hemodiafiltration: a Historical Cohort of a Single-center in South East Asia

Conditions
-----------------
End-stage Renal Disease

Intervention / Treatment
-----------------
* Other: Hemodiafiltration


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged 18 years or more Be diagnosed end-stage renal disease for more than one year Have been regularly received long-term hemodiafiltration for more than 6 months. Exclusion Criteria: Patients who received hemodiafiltration less than 6 months

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Hemodiafiltration<br>End-stage renal disease patients who were treated with high-efficiency hemodiafiltration for more than 6 months | Other: Hemodiafiltration<br>* Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival rate | The Kaplan-Meier survival curve and mean survival time will be demonstrated for primary outcome. | 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Comparison of survival differences between patients who start renal replacement therapy with HDF and who switched from hemodialysis as well as between diabetic and non-diabetic patient. | Survival differences between groups will be evaluated with the Kaplan-Meier method and compared using the log-rank test. The comparative groups include: Patient who start renal replacement therapy with HDF (incident cases) vs. who switched from hemodialysis (prevalence cases) Diabetic vs. Non-diabetic patients | 10 years | 
| Factors that associated with all-cause mortality | univariate and multivariate analysis the factors that might affected the long-term outcomes. The factors include dialytic parameters (spKt/Vurea, TAC urea), nutritional parameters (nPNA, albumin), inflammatory parameter (hsCRP), and biochemical parameters (BUN, Cr, Ca, Phosphate, iPTH, beta2-microglobulin, Hb, Ferritin, Transferrin saturation, Cholesterol, Triglyceride, HDL, and LDL) | 10 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Survival, Hemodiafiltration, End-stage renal disease, Hemodialysis